Immunotherapy Combo Offers Slight Survival Benefit in Melanoma [News in Brief]

Data on 2-year survival in the phase III CheckMate 067 trial testing nivolumab plus ipilimumab showed a slight survival benefit for the combination over nivolumab monotherapy—but the difference may not be dramatic enough to justify using the combination given the added side effects.

from Cancer via ola Kala on Inoreader http://ift.tt/2ri98VO
via IFTTT